AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39266961 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of CBD (5 mg CBD/kg/day to 30 mg CBD/kg/day, escalated every two weeks in increments of 5 mg CBD/kg/day)
Number of subjects: 40
Study 39266985 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Pulpotomy (TP)
Number of subjects: 64
Study 39266985 — intervention group
Group type: COMPARATOR
Intervention: Root Canal Treatment (RCT)
Number of subjects: 64
Study 39267006 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 0
Study 39267006 — intervention group
Group type: COMPARATOR
Intervention: Delivery by obstetrician
Number of subjects: 0
Study 39267006 — intervention group
Group type: COMPARATOR
Intervention: Birth in hospital
Number of subjects: 0
Study 39267010 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (moderate intensity exercise with exercise physiologists 3 days/week for 16 weeks)
Number of subjects: 100
Study 39267010 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 39267015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofortified adhesive (titanium dioxide nanoparticles)
Number of subjects: 60
Study 39267015 — intervention group
Group type: COMPARATOR
Intervention: Conventional adhesive (without nanoparticles)
Number of subjects: 60
Study 39267042 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (RC) levels in patients with LVH
Number of subjects: 630
Study 39267042 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of RC
Number of subjects: 630
Study 39267052 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 incidence rate
Number of subjects: 32223
Study 39267052 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 mortality rate
Number of subjects: 32223
Study 39267085 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided adaptive radiotherapy (MRgART) with simultaneous integrated boost (SIB) (60-65 Gy in 25-28 fractions to primary lesions and positive lymph nodes; 50-50.4 Gy in 25-28 fractions to the pelvis)
Number of subjects: 128
Study 39267085 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (50-50.4 Gy in 25-28 fractions)
Number of subjects: 128
Study 39267085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups receive concurrent chemotherapy with capecitabine and consolidation chemotherapy of either two cycles of CAPEOX or three cycles of FOLFOX between radiotherapy and surgery
Number of subjects: 128
Study 39267092 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + video feedback observation (IO)
Number of subjects: 16
Study 39267092 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + observation + vibratory feedback (IOV)
Number of subjects: 16
Study 39267092 — intervention group
Group type: COMPARATOR
Intervention: MI alone (IA)
Number of subjects: 16
Study 39267092 — intervention group
Group type: COMPARATOR
Intervention: MI + vibratory feedback (IV)
Number of subjects: 16
Study 39267112 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma transcranial alternating current stimulation (tACS) at 40 Hz for 30 one-hour sessions over 15 days
Number of subjects: 46
Study 39267112 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 46
Study 39267183 — intervention group
Group type: EXPERIMENTAL
Intervention: My Anesthesia Choice─Hip Fracture conversation aid
Number of subjects: 0
Study 39267183 — intervention group
Group type: COMPARATOR
Intervention: Baseline data
Number of subjects: 0
Study 39267183 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation period
Number of subjects: 0
Study 39267224 — intervention group
Group type: COMPARATOR
Intervention: Online psychoeducational program
Number of subjects: 100
Study 39267224 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychoeducational program integrated with VR
Number of subjects: 100
Study 39267408 — intervention group
Group type: EXPERIMENTAL
Intervention: MTx.100 Column plus standard of care (SOC), n=70
Number of subjects: 107
Study 39267408 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) only, n=244
Number of subjects: 107
Study 39267574 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine (0.2 g, three times/day) + PD-1/PD-L1 inhibitor
Number of subjects: 172
Study 39267574 — intervention group
Group type: COMPARATOR
Intervention: Non-inosine (PD-1/PD-L1 inhibitor ± targeted ± chemotherapy)
Number of subjects: 172
Study 39267685 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized mRNA vaccine (1 mg every 3 weeks for 4 cycles) combined with PD-1 inhibitor therapy.
Number of subjects: 1
Study 39267685 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor therapy (single dose 8 weeks after the 4th cycle).
Number of subjects: 1
Study 39268031 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial temporal interference stimulation (tTIS)
Number of subjects: 0
Study 39268031 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 39268119 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) after early extubation for 48 hours
Number of subjects: 0
Study 39268119 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (Venturi mask or nasal goggles) after early extubation for 48 hours
Number of subjects: 0
Study 39268602 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean levels of total cholesterol, LDL-C, and non-HDL-C
Number of subjects: 2395
Study 39268602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-SD increment of lipid variability (LDL-C)
Number of subjects: 2395
Study 39268602 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated variability in LDL-C and non-HDL-C
Number of subjects: 2395
Study 39268602 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining consistently low levels of atherogenic lipids
Number of subjects: 2395
Study 39268670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic delta (DD) and videodensitometry assessment
Number of subjects: 51
Study 39268670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic delta (DD)
Number of subjects: 51
Study 39268670 — intervention group
Group type: EXPERIMENTAL
Intervention: Videodensitometry
Number of subjects: 51
Study 39268670 — intervention group
Group type: COMPARATOR
Intervention: Cardiac magnetic resonance
Number of subjects: 51
Study 39268699 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of bepirovirsen in participants with hepatic impairment (HI)
Number of subjects: 0
Study 39268699 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy participants (HPs)
Number of subjects: 0
Study 39268760 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasty using a direct lateral approach
Number of subjects: 23
Study 39268760 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasty using an anterolateral approach
Number of subjects: 23
Study 39268857 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg)
Number of subjects: 730
Study 39268857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 39268857 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 730
Study 39268981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy (IFRT)
Number of subjects: 34
Study 39269392 — intervention group
Group type: EXPERIMENTAL
Intervention: SC furosemide
Number of subjects: 51
Study 39269392 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 51
Study 39269400 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator performing ≥32 LAAOs annually
Number of subjects: 1547
Study 39269400 — intervention group
Group type: COMPARATOR
Intervention: Operators performing <32 LAAOs annually
Number of subjects: 1547
Study 39269413 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion measured at rest and under stress using cardiac magnetic resonance; assessed myocardial blood flow (MBF) and myocardial perfusion reserve (MPR).
Number of subjects: 453
Study 39269413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress MBF measurements.
Number of subjects: 453
Study 39269413 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress MBF and MPR.
Number of subjects: 453
Study 39269415 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG >0.65
Number of subjects: 95
Study 39269415 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR ≤0.70
Number of subjects: 95
Study 39269415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PPG >0.65 and FFR ≤0.70
Number of subjects: 95
Study 39269606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions
Number of subjects: 22
Study 39269704 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete SCH intervention (group 5)
Number of subjects: 757
Study 39269704 — intervention group
Group type: EXPERIMENTAL
Intervention: NP follow-up (group 3)
Number of subjects: 757
Study 39269704 — intervention group
Group type: COMPARATOR
Intervention: Self-management coaching (group 1)
Number of subjects: 757
Study 39269704 — intervention group
Group type: COMPARATOR
Intervention: NP follow-up (group 4)
Number of subjects: 757
Study 39269742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Care Self-Efficacy Index in Oral Anticoagulation Therapy Management (SCSE-OAC)
Number of subjects: 0
Study 39269742 — intervention group
Group type: EXPERIMENTAL
Intervention: SCSE-OAC
Number of subjects: 0
Study 39269759 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide with lifestyle counseling
Number of subjects: 20
Study 39269759 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling without semaglutide
Number of subjects: 20
Study 39269839 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tACS
Number of subjects: 46
Study 39269839 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 46
Study 39269850 — intervention group
Group type: EXPERIMENTAL
Intervention: 24(S)-Hydroxycholesterol (24(S)-OHC)
Number of subjects: 0
Study 39269850 — intervention group
Group type: EXPERIMENTAL
Intervention: 24(S)-OHC
Number of subjects: 0
Study 39269850 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-OHC and 27-OHC
Number of subjects: 0
Study 39270145 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Transplantation
Number of subjects: 0
Study 39270145 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Transplantation
Number of subjects: 0
Study 39270146 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of highly structured aerobic exercise training (AT)
Number of subjects: 64
Study 39270146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 64
Study 39270144 — intervention group
Group type: EXPERIMENTAL
Intervention: IGLON5 autoantibodies
Number of subjects: 339
Study 39270144 — intervention group
Group type: EXPERIMENTAL
Intervention: CASPR2 autoantibodies
Number of subjects: 339
Study 39270144 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms associated with IGLON5 and CASPR2 cases
Number of subjects: 339
Study 39270144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical implications of findings
Number of subjects: 339
Study 39270151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin (days 1-21) followed by clopidogrel (days 22-90)
Number of subjects: 6100
Study 39270151 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone for 90 days
Number of subjects: 6100
Study 39270205 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 84
Study 39270205 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care rehabilitation
Number of subjects: 84
Study 39270307 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Hot Weather Combat Uniform (IHWCU)
Number of subjects: 12
Study 39270307 — intervention group
Group type: EXPERIMENTAL
Intervention: Army Combat Uniform (ACU)
Number of subjects: 12
Study 39270307 — intervention group
Group type: EXPERIMENTAL
Intervention: ACU with silk-weight base layer (ACU+)
Number of subjects: 12
Study 39270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab with chemotherapy
Number of subjects: 719
Study 39270380 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 719
Study 39270623 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum neurofilament light (NfL)
Number of subjects: 0
Study 39270623 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NfL
Number of subjects: 0
Study 39270623 — intervention group
Group type: EXPERIMENTAL
Intervention: NfL
Number of subjects: 0
Study 39270623 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood NfL
Number of subjects: 0
Study 39270623 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined thresholds of NfL
Number of subjects: 0
Study 39270686 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin efsitora alfa
Number of subjects: 893
Study 39270686 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 893
Study 39270695 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg once daily for patients with bodyweight ≥50 kg; 400 mg once daily for patients with bodyweight <50 kg, administered in 21-day cycles.
Number of subjects: 87
Study 39270695 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib
Number of subjects: 87
Study 39270701 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of the intervention (specific intervention not provided in the abstract)
Number of subjects: 332
Study 39270702 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, venetoclax, and obinutuzumab combination
Number of subjects: 28
Study 39270747 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism Eats program
Number of subjects: 51
Study 39270828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) for oligoprogressive disease in 1 to 5 fractions while maintaining systemic therapy (ST)
Number of subjects: 70
Study 39270828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 70
Study 39270937 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using 20-40 predictors
Number of subjects: 12
Study 39270937 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models for multiclass classification
Number of subjects: 12
Study 39270937 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression models using 36 variables
Number of subjects: 12
Study 39270937 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of predictors
Number of subjects: 12
Study 39270940 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with severe MR
Number of subjects: 631
Study 39270940 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with moderate MR
Number of subjects: 631
Study 39270940 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with mild MR
Number of subjects: 631
Study 39270940 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI with no or trace MR
Number of subjects: 631
Study 39270940 — intervention group
Group type: COMPARATOR
Intervention: Control group (other degrees of MR)
Number of subjects: 631
Study 39271104 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous daptomycin (10 mg/kg)
Number of subjects: 12
Study 39271104 — intervention group
Group type: COMPARATOR
Intervention: Intravenous daptomycin (10 mg/kg)
Number of subjects: 12
Study 39271104 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous placebo (NaCl 0.9%)
Number of subjects: 12
Study 39271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.16 mg/kg/week
Number of subjects: 62
Study 39271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.20 mg/kg/week
Number of subjects: 62
Study 39271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.24 mg/kg/week
Number of subjects: 62
Study 39271158 — intervention group
Group type: COMPARATOR
Intervention: Daily GH 0.035 mg/kg/day
Number of subjects: 62
Study 39271158 — intervention group
Group type: COMPARATOR
Intervention: Daily GH 0.067 mg/kg/day
Number of subjects: 62
Study 39271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan
Number of subjects: 62
Study 39271158 — intervention group
Group type: COMPARATOR
Intervention: Daily GH
Number of subjects: 62
Study 39271158 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan and Daily GH
Number of subjects: 62
Study 39271520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 46
Study 39271521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily
Number of subjects: 60
Study 39271642 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) using EYE-LIGHT
Number of subjects: 76
Study 39271642 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 76
Study 39271844 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 39271927 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensor data (step count, resting heart rate, sleep quantity)
Number of subjects: 553
Study 39271928 — intervention group
Group type: EXPERIMENTAL
Intervention: ICVB-1042 administered intravenously or intratumorally
Number of subjects: 0
Study 39271928 — intervention group
Group type: EXPERIMENTAL
Intervention: ICVB-1042 administered intravenously
Number of subjects: 0
Study 39271928 — intervention group
Group type: EXPERIMENTAL
Intervention: ICVB-1042
Number of subjects: 0
Study 39271938 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitored use (SM)
Number of subjects: 558
Study 39271938 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported use (PS)
Number of subjects: 558
Study 39271938 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically integrated model (CI)
Number of subjects: 558
Study 39271956 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with SLOS
Number of subjects: 0
Study 39271956 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher severity scores
Number of subjects: 0
Study 39271956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower initial cholesterol levels
Number of subjects: 0
Study 39272058 — intervention group
Group type: EXPERIMENTAL
Intervention: F-627 (efbemalenograstim alfa) 20 mg once per cycle
Number of subjects: 239
Study 39272058 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 µg/kg/d) daily
Number of subjects: 239
Study 39272087 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence assessment of vascular supply of post-resection pancreatic remnant
Number of subjects: 0
Study 39272087 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence assessment
Number of subjects: 0
Study 39272087 — intervention group
Group type: COMPARATOR
Intervention: High-risk group for pancreatic fistula development
Number of subjects: 0
Study 39272087 — intervention group
Group type: COMPARATOR
Intervention: Postoperative data collection
Number of subjects: 0
Study 39272101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-mA transcranial direct current stimulation (tDCS) targeting the left dorsolateral prefrontal cortex (F3) and right frontopolar cortex (Fp2)
Number of subjects: 40
Study 39272101 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 39272117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement in the RECOVAC project
Number of subjects: 0
Study 39272117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement process
Number of subjects: 0
Study 39272117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement
Number of subjects: 0
Study 39272117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient representatives' involvement
Number of subjects: 0
Study 39272117 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline for patient engagement
Number of subjects: 0
Study 39272114 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week resistance training intervention (RTI)
Number of subjects: 57
Study 39272114 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with unchanged low physical activity
Number of subjects: 57
Study 39272125 — intervention group
Group type: EXPERIMENTAL
Intervention: P-STEP® mobile app
Number of subjects: 380
Study 39272144 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 21
Study 39272144 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary instruments
Number of subjects: 21
Study 39272144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 21
Study 39272164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative medication reviews conducted by MipAC physicians, supervised by geriatricians, and in collaboration with general practitioners
Number of subjects: 100
Study 39272164 — intervention group
Group type: COMPARATOR
Intervention: Usual care at the MipAC unit
Number of subjects: 100
Study 39272164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative medication reviews
Number of subjects: 100
Study 39272196 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-based multicomponent personalized preventive program (PPP)
Number of subjects: 1216
Study 39272196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 1216
Study 39272210 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Remediation Therapy (TCRT)
Number of subjects: 13
Study 39272232 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CD serology screening for antitissue transglutaminase antibodies in individuals with predisposing HLA-DQ2/DQ8 genotypes.
Number of subjects: 2832
Study 39272232 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian ethnicity
Number of subjects: 2832
Study 39272232 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ethnicity
Number of subjects: 2832
Study 39272232 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown ethnicity
Number of subjects: 2832
Study 39272232 — intervention group
Group type: EXPERIMENTAL
Intervention: East Asian ethnicity
Number of subjects: 2832
Study 39272232 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian ethnicity
Number of subjects: 2832